About a company IDEC disambiguation IDEC Infobox company company name BiogenIdec, Inc. company logo Image BiogenIdec logo.png company type Public company Public traded as nasdaq BIIB br NASDAQ 100 NASDAQ ... 10 K, BiogenIdec, Inc. publisher United States Securities and Exchange Commission ref operating income ... homepage http www.biogenidec.com BiogenIdec.com BiogenIdec, Inc. nasdaq BIIB is an American biotechnology ... . BiogenIdec stock is a component of several stock indices such as the S&P 500 , S&P 1500 , and NASDAQ 100 . Products BiogenIdec s products include multiple sclerosis MS treatments Avonex interferon ... marketed with lan . BiogenIdec also makes Rituxan rituximab , a treatment for non Hodgkin s lymphoma ... BiogenIdec 2008 . Product Pipeline in 2007 Annual Report ref The company acquired Fumaderm fumaric ..., 2007, BiogenIdec sold the U.S. rights for Zevalin ibritumomab tiuxetan , another treatment ... sec10k2007 cite web title SEC Form 10 K author BiogenIdec pages 1, 11 url http edgar.sec.gov Archives ... date 2011 10 26 ref Locations of operation BiogenIdec is headquartered in Weston, Massachusetts , and operates research and development facilities in Cambridge, MA. BiogenIdec operates manufacturing ... built a Large Scale Manufacturing plant in Hiller d , Denmark . BiogenIdec maintains its international ... of excellence in Maidenhead, UK. BiogenIdec has direct commercial affiliates in Germany , France ... , Canada , Japan , China , India and Australia . In Italy and in Switzerland , BiogenIdec markets ... Dompe Biotec. Competitors BiogenIdec s principal competitors include Teva Pharmaceutical Industries .... Roche markets Rituxan outside the US as MabThera. Management BiogenIdec is managed day to day by an executive ... author BiogenIdec url http www.biogenidec.com site board of directors.html accessdate 2008 06 06 ... three of his own nominees to the BiogenIdec board at the company s June 19, 2008 annual meeting ... were elected. Natalizumab withdrawal On February 28, 2005, BiogenIdec and marketing partner ... more details
IDEC can refer to BiogenIdec , a biotechnology company IDEC Corporation , a manufacturer of Automation and Control products Interior Design Educators Council International Democratic Education Conference , an annual academic and youth conference Toralizumab IDEC 131 , an antibody and an immunosuppressive drug Trimaran IDEC , a ship that won the round the world record in 2008 disamb ... more details
About a manufacturer IDEC disambiguation IDEC Infobox company company name IDEC company logo Image IDEC Corporation Logo.png 200px company type Public company Public tyo 6652 slogan Think Automation and beyond... foundation 1945 num employees 1,664 industry Industrial Automation location Osaka , Japan homepage http www.idec.com www.idec.com IDEC Corporation tyo 6652 , formerly IDEC Izumi Corporation, is a manufacturer of Automation and Control products. The company was founded in Osaka Japan in 1945. IDEC was founded by Tsuneo Funaki, in 1945 and it became a company organization in 1947. IDEC is known for their various electromechanical control products such as relays, timers, and switches. The company also manufactures automation products, such as Micro Programmable logic controller s, power supplies, and touch screen displays. In addition to supplying automation and control products, other divisions of the company supply sensors, bar code readers, and advanced LED opto electronic components. Category Companies based in Osaka Prefecture japan company stub ja IDEC ... more details
About a ship IDEC disambiguation IDEC Image Trimaran idec brest 2008 1.JPG right thumb 300px Francis Joyon on Trimaran IDEC , arriving from his round the world voyage, in only 57 days Trimaran IDEC or Idec 2 is a maxi trimaran skippered by Francis Joyon and sponsored par groupe IDEC . The main goal of Francis Joyon was to regain the single handed Around the world sailing record round the world record from Ellen MacArthur . The yachtsman from Locmariaquer did so, in January 2008, beating her record by more than two weeks, and even managed to get the second best time around the world behind Orange II and in front of crewed sailboats such as Cheyenne catamaran Cheyenne , Geronimo yacht G ronimo and Orange yacht Orange . Description ref name descrip http www.trimaran idec.com trimaran descriptif.asp Trimaran IDEC website ref Launched 2007 Total length 29.70 m 97 ft Length of side hulls 24.5 m 80 ft Width 16.5 m 54 ft Weight 11 t Sails 350 m 520 m Mast height 32 m 105 ft Records 2007 24 hours distance record Single handed sailing single handed ref name record24h http www.sailspeedrecords.com 24 hour distance.html WSSRC 24h records ref convert 616.07 nmi km 2007 Channel crossing record Cowes to Dinard , the 19 August 2007, in 6h 23m and 36s, at an average speed of convert 21.58 kn km h . ref name WSSRC ratified passage records http www.sailspeedrecords.com wssrc ratified passage records.html WSSRC ratified passage records ref 2008 Around the world sailing record Around the world record single handed, non stop and with no assistance 57d 6h 23m 6s, with an average speed of convert 21.6 kn km h . ref name WSSRC ratified passage records It also ... IDEC http www.trimaran idec.com trimaran IDEC website http www.voile multicoques.com 3.html Voile Multicoques.com trimaran Idec 2 . Category Trimarans Category Individual sailing vessels fr Trimaran IDEC ... more details
James L. Jim Vincent was the Chairman and CEO of BiogenIdec from 1985 to 2002. He graduated from Duke University s Pratt School of Engineering in 1961 with a Bachelor of Science degree. He received an MBA from the Wharton School of Business at the University of Pennsylvania in 1963. He is currently a member of the Board of Directors of Alnylam Pharmaceuticals and Board of Trustees of Duke University. He has two children, Aimee Jamison and Christopher Vincent. ref http www.nytimes.com 1997 10 12 style weddings aimee vincent jeremiah jamison.html ref Vincent is credited with decisions leading to the financial stability and success of Biogen in the late 1980s and early 1990s. ref http www.strategy business.com press 16635507 18003 ref ref http media.www.whartonjournal.com media storage paper201 news 2001 09 24 News Alum Of.The.Week.James.Vincent 99733.shtml ref Early career Prior to working in the healthcare industry, Vincent held senior positions at Texas Instruments in Europe and Japan. He chose to leave TI, and then joined Abbott Laboratories , as the Founding President of its Human Diagnostics Division. ref http www.fuqua.duke.edu admin extaff news publications ex sum2003.pdf ref He rose to President and Chief Operating Officer of Abbott. He then became the President of Allied Health and Scientific Products. ref http www.fuqua.duke.edu admin extaff news publications ex sum2003.pdf ref Biogen turnaround In 1985, he left Allied to take the President and CEO role of Biogen. Biogen, having raised and spent vast sums of money in the early 1980s without delivering a stream of revenue generating product, was teetering on the brink, with mounting losses and no way to raise more money, when he joined. ref http www.strategy business.com press 16635507 18003 ref Vincent s initial ... Biogen had in place with other pharma companies. ref http www.strategy business.com press 16635507 18003 ref With a viable burn rate in place enabling Biogen to survive, Vincent built and executive ... more details
Howard Civian Birndorf is a biotechnology entrepreneur and one of the founders of the biotech industry in San Diego, California . ref name forbes cite web url http people.forbes.com profile howard c birndorf 55580 title Forbes.com Howard C. Birndorf accessdate 2010 01 30 work forbes.com ref Along with former University of California professor and current venture capitalist Ivor Royston , Birndorf founded San Diego s first biotech in 1978, the monoclonal antibody company Hybritech. The company was subsequently bought by Eli Lilly and Company in 1986, and Birndorf went on to found a number of other successful companies including Gen Probe , IDEC Pharmaceuticals which merged with Biogen to form Biogen Idec , and Ligand. Birndorf was also involved in the formation of Gensia Sicor , was a founding investor of Kiyon, and was a founding Director of Neurocrine Biosciences . Birndorf was Chairman of the Board and founding Director of FasTraQ , Chairman of HA Cell Technology and was Chairman of Oy Jurilab , a Finland Finnish genomics company. He is a founder and co chair of the Coalition for 21st Century Medicine and was founder, Chairman and CEO of Nanogen, Inc . Birndorf received his B.A. in Biology from Oakland University , an M.S. in Biochemistry from Wayne State University , and has received honorary Doctor of Science degrees from Oakland University and Wayne State University. References reflist Persondata Metadata see Wikipedia Persondata . NAME Birndorf ALTERNATIVE NAMES SHORT DESCRIPTION DATE OF BIRTH PLACE OF BIRTH DATE OF DEATH PLACE OF DEATH DEFAULTSORT Birndorf Category Living people Category Year of birth missing living people Category People from California Category Oakland University alumni Category Wayne State University alumni ... more details
Paul Appermont born in Bilzen in 1946 is a Belgium Belgian businessman. Together with Joos Horsten , he laid the foundation of Janssen Pharmaceutica Xi an Janssen Pharmaceutical . ref http themedicalcentera.blogspot.com 2007 08 01 archive.html The Medical Center August 2007 Bot generated title ref Appermont is a member of the board of EuropaBio . Education Appermont graduated with a Ph.D in Law at the Katholieke Universiteit Leuven Leuven , Belgium ref http www.abfx.com mashpipe Category Leuven alumni Category leuven Alumni mashPipe Bot generated title ref and in International Relations at the Graduate Institute of International Studies IUHEI Geneva , Switzerland . Career Paul Appermont started his career at Janssen Pharmaceutica as company lawyer . In 1979 he and Joos Horsten were sent to Xi an , the capital of Shaanxi province, in the People s Republic of China by Dr. Paul Janssen to prepare for the establishment of a pharmaceutical company . In 1986 he started working for Biogen Idec Biogen in Switzerland as a Vice President of trade and licensing. In 1896 he joined Jean Louis Gentilini in the development of Medicard . He now works as a consultant for Innogenetics and the biotech industry. ref http www.investinflanders.com en news details default.aspx?id 7703baa6 4135 4aa3 9bd1 f1aae8933ed0&news First Flanders biotech seminar in Japan huge success&parent af2ecb9b ab1b 42d4 acd9 7e377bcd80b8 First Flanders biotech seminar in Japan huge success Bot generated title ref Notes reflist References Trends, Ik ben Paul Janssen nog altijd dankbaar , 24 April 2008, pp. 132 135 http www.europabio.org articles article 19 EN.pdf Europabio board Geerdt Magiels, Paul Janssen. Pionier in farma en in China , Houtekiet, 2005. Persondata Metadata see Wikipedia Persondata . NAME Appermont, Paul ALTERNATIVE NAMES SHORT DESCRIPTION businessman DATE OF BIRTH 1946 PLACE OF BIRTH Bilzen, Belgium DATE OF DEATH PLACE OF DEATH Use dmy dates date June 2011 DEFAULTSORT Appermont, Paul Cat ... more details
Drugbox Verifiedfields changed verifiedrevid 458274979 image Monoclonal antibody data type mab mab type mab source xi i target CD80 Clinical data tradename pregnancy AU pregnancy US pregnancy category legal AU legal CA legal UK legal US legal status routes of administration Pharmacokinetic data bioavailability protein bound metabolism elimination half life excretion Identifiers CAS number Ref cascite changed ?? CAS number 357613 77 5 ATC prefix none ATC suffix PubChem DrugBank Ref drugbankcite correct drugbank UNII Ref fdacite correct FDA UNII S9OX9692ZB KEGG Ref keggcite correct kegg KEGG D04295 ChemSpiderID Ref chemspidercite correct chemspider ChemSpiderID NA Chemical data chemical formula molecular weight Galiximab is a monoclonal antibody designed for the treatment of B cell lymphoma . As of September 2009 , it is undergoing Phase III clinical trial s. ref http www.biogenidec.com site pipeline.html Biogen Idec Pipeline ref The drug is a chimeric protein chimeric antibody from Macaca irus and Homo sapiens . ref http whqlibdoc.who.int druginfo INN 2004 list51.pdf WHO Drug Information ref References reflist External links http www.biogenidec.com Official website immunosuppressants Monoclonals for immune system Category Monoclonal antibodies monoclonal antibody stub antineoplastic drug stub it Galiximab ... more details
Drugbox Verifiedfields changed verifiedrevid 470631639 image Monoclonal antibody data type mab mab type mab source xi o target 5 1 integrin Clinical data tradename pregnancy AU pregnancy US pregnancy category legal AU legal CA legal UK legal US legal status routes of administration Pharmacokinetic data bioavailability protein bound metabolism elimination half life excretion Identifiers ChemSpiderID Ref chemspidercite correct chemspider ChemSpiderID NA CAS number Ref cascite changed ?? CAS number 558480 40 3 ATC prefix none ATC suffix PubChem DrugBank Ref drugbankcite correct drugbank DrugBank UNII Ref fdacite correct FDA UNII 496K5Z02NW KEGG Ref keggcite correct kegg KEGG D06319 Chemical data C 6434 H 9942 N 1706 O 2040 S 52 molecular weight 145.5 kDa Volociximab also known as M200 is a Chimeric protein chimeric monoclonal antibody jointly developed by PDL BioPharma and Biogen Idec for treatment of a variety of advanced solid tumor s. It binds to and inhibits the functional activity of 5 1 integrin . ref cite journal pmid 19468731 year 2009 last1 Ng first1 CM last2 Bai last3 Takimoto last4 Tang last5 Tolcher title Mechanism based receptor binding model to describe the pharmacokinetic and pharmacodynamic of an anti alpha 5 beta 1 integrin monoclonal antibody volociximab in cancer patients doi 10.1007 s00280 009 1023 8 journal Cancer chemotherapy and pharmacology first2 S first3 CH first4 MT first5 AW volume 65 pages 207 17 issue 2 ref It is thought to reduce metastases. Early results show potential in renal cell cancers. ref needed References reflist External links http www.pdl.com index.cfm?navId 54 Official website Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems Category Monoclonal antibodies for tumors monoclonal antibody stub antineoplastic drug stub ... more details
Notability date December 2007 Primary sources date December 2007 BLP sources May 2012 Commented out because image was deleted Image Sylvie Gregoire.jpg thumb right Dr. Sylvie Louise Gr goire , PharmD is a Massachusetts biotechnology and pharmaceutical company executive. She is currently the President of the Human Genetics division at Shire plc . Gregoire has a doctorate in Pharmacy and Pharmacology. Sylvie Gregoire is also a dual US and Canadian citizen, lives in Boston, Massachusetts and is active in philanthropy in the Boston area. Citation needed date February 2011 Prior to being the President of one of Shire plc s two divisions she was the chairwoman of the board of drug company IDM Pharma she was also a board member of Cubist Pharmaceuticals CBST and Caprion Proteomics. In addition, Gregoire was also President and Chief Executive Officer of Glycofi Inc. now a wholly owned subsidiary of Merck & Co. and the Executive Vice President of Biogen Idec . Education Universit Laval Laval University , Quebec City, Canada Faculty of Pharmacy University at Buffalo Doctorate of Pharmacy Community involvement Member of the board of trustees of the International School of Boston Member of the board of the Greater Boston Food Bank Active in the Accelerated Cure Project a charity committed to curing Multiple Sclerosis Citation needed date February 2011 External links and references http www.shire.com shire InvestorRelations regulatorynews item.jsp?ric SHP.L&ref 18568 Shire plc press release announcing Sylvie Gregoire as President of the Human Genetics division http www.cubist.com about bod.php Cubist Pharmaceuticals website page describing Sylvie Gr goire and the company s board of directors Persondata Metadata see Wikipedia Persondata . NAME Gregoire, Sylvie ALTERNATIVE NAMES SHORT DESCRIPTION DATE OF BIRTH PLACE OF BIRTH DATE OF DEATH PLACE OF DEATH DEFAULTSORT Gregoire, Sylvie Category Canadian women in business Category University at Buffalo alumni Category Living people ... more details
Richard C. Mulligan , Ph.D., born 1954 is the Mallinckrodt Professor of Genetics at Harvard Medical School, ref http genetics.med.harvard.edu faculty mulligan ref ref http www.hms.harvard.edu dms bbs fac mulligan.html ref ref http www.dfhcc.harvard.edu membership profile member 689 0 ref and Director of the Harvard Gene Therapy Initiative. ref http people.forbes.com profile richard c mulligan 43072 Richard C. Mulligan , Forbes ref He is a Director of Enzon Pharmaceuticals, Inc. , ref http www.enzon.com index.php?id 175 ref and Biogen Idec, Inc. . ref http articles.latimes.com 2009 jun 04 business fi briefs4.S3 ref Awards 1981 MacArthur Fellows Program 1983 Searle Scholar ref http www.searlescholars.net person 419 ref Works Lindemann, D., Patriquin, E., Feng, S. and Mulligan, R.C. 1997 Versatile retovirus vector systems for regulated gene expression in vitro and in vivo . Molecular Medicine 3 466 476. Goodell, M.A., Rosenzweig, H .K., Marks, D.G., DeMaria, M., Paradis, G., Grupp, S.A., Sieff, C.A., Mulligan, R.C. and Johnson, R.P. 1997. Dye efflux studies suggest the existence of CD34 negative low hematopoietic stem cells in multiple species . Nature Medicine 3 1337 1345. Mach, N., Lantz, C.S., Galli, S.J., Reznikoff, G., Mihm, M., Small, C., Granstein, R., Beissert, S., Sadelain, M., Mulligan, R.C. and Dranoff, G. 1998. Involvement of interleukin 3 in delayed type hypersensitivity . Blood 92 778 783. References reflist External links http scholar.google.com scholar?q Richard 20C. 20Mulligan&um 1&lr &sa N&hl en&tab ps Richard C. Mulligan , Google Scholar Persondata Metadata see Wikipedia Persondata . NAME Mulligan, Richard C. ALTERNATIVE NAMES SHORT DESCRIPTION DATE OF BIRTH 1954 PLACE OF BIRTH DATE OF DEATH PLACE OF DEATH DEFAULTSORT Mulligan, Richard C. Category 1954 births Category MacArthur Fellows Category Harvard Medical School faculty Category Living people no Richard C. Mulligan ... more details
Orphan date February 2009 This article is primarily about Genetics Institute prior to its 1995 acquisition by Wyeth. For the current company, see Wyeth . Infobox Defunct company company name Genetics Institute, Inc. company type Defunct foundation 1980 defunct 1996 fate acquisition by Wyeth successor Wyeth location Cambridge, MA , USA industry Biotechnology Genetics Institute, Inc. Genetics Institute was a biotechnology research and development company founded by Thomas Maniatis and Mark Ptashne , two Harvard molecular biologists, in 1980 in Massachusetts. Originally operating out of Ptashne s house in Boston, the company found more spacious quarters first in Boston and then Cambridge before expanding further. Gabriel Schmergel joined soon afterwards as CEO. ref name about.com cite web url http www.answers.com topic genetics institute inc title Genetics Institute Inc authorlink Elizabeth Rourke accessdate 2009 01 01 ref Many leading scientists joined G.I. from academia and it proved to be a fertile source of patents for some time. ref name Breschi and Malerba cite book title Clusters, Networks, and Innovation editors Stefano Breschi and Franco Malerba publisher Oxford University Press date 2005 ISBN 0199275556 pages 263, 281 ref Historical background One of the two largest national clusters of biotechnology in the U.S. the other being the San Francisco Bay area , the greater Boston area has been the birthplace of many innovative corporations and non profit research centers. Beginning in the late seventies and eighties, this biotech trend saw three early large for profit corporations Biogen now Biogen Idec , Genzyme , and Genetics Institute. MIT s Whitehead Institute was one of the seminal non profit research centers in this field locally, among many others. Aside from MIT, Harvard, Boston University and several teaching hospitals including Massachusetts General Hospital and Brigham and Women s were important contributors to the local field s development. ref name Br ... more details
NOTOC div style float left width 69 Biotechnology is a technology based on biology , especially when used in agriculture , food science , and medicine . Of the many different definitions available, the one formulated by the UN Convention on Biological Diversity is one of the broadest Biotechnology means any technological application that uses biological systems, living organisms, or derivatives thereof, to make or modify products or processes for specific use. Article 2. Use of Terms div style text align right margin right 10px margin bottom 4px Biotechnology More about Biotechnology... div div div style float right width 29 Biotechnology title MINUTE CURRENTTIME t div br style clear both see also Outline of biotechnology This page provides an alphabetical list of articles and other pages including categories, lists, etc. about biotechnology. For other overviews of the topic, please see the Portal Biotechnology Biotechnology portal . A Agrobacterium Affymetrix Alcoholic beverages Category Alcoholic beverages Amgen AnaSpec Antibiotic Artificial selection B Biochemical engineering Biochip Biodiesel Bioengineering Biofuel Biogas Biogen Idec Bioindicator Bioinformatics Category Bioinformatics Bioleaching Biological agent Biological warfare Bioluminescence Biomimetics Bionanotechnology Bionics Biopharmacology Biophotonics Bioreactor Bioremediation Biostimulation Biosynthesis Biotechnology Category Biotechnology Category Biotechnology companies Category Biotechnology products Bt corn BioSynergy C Cancer immunotherapy Cell therapy Chimera genetics Chinese hamster Chinese Hamster Ovary cell Chiron Corp. Cloning Compost Composting Convention on Biological Diversity Chromatography D Directive on the patentability of biotechnological inventions DNA microarray Dwarfing E Enzymes Electroporation Environmental biotechnology Eugenics F fermentation food Fermentation Category Fermented foods G Gene knockout Gene therapy Genentech Genetic engineering Genetically modified food Geneti ... more details
Edward H. Linde c. 1942 &ndash January 10, 2010 was a real estate developer and philanthropist in Boston, Massachusetts . ref name Ross cite web url http www.boston.com bostonglobe obituaries articles 2010 01 12 developer hub benefactor edward linde dead at 68 ?page 2 title Developer, Hub benefactor Edward Linde dead at 68 first Casey last Ross publisher Boston Globe date 2010 01 12 ref ref cite web url http www.bostonherald.com business general view 20100112edward linde recalled for fine projects good works title Edward Linde recalled for fine projects, good works first Thomas last Grillo coauthors Ira Kantor publisher Boston Herald date 2009 01 12 ref ref name MIT cite web url http web.mit.edu newsoffice 2010 obit linde 0111.html title Edward Linde 62, former MIT Corporation member, dies at age 68 Real estate investor s generous gift helped publicly launch MIT s Campaign for Students publisher MIT News date 2010 01 11 ref Alongside Mortimer B. Zuckerman , he co founded Boston Properties in 1970. ref name Ross Linde was chairman of the board of the Boston Symphony Orchestra , a director of Jobs for Massachusetts , WGBH TV WGBH , and Boston World Partnership , and a trustee at the Beth Israel Deaconess Medical Center . ref name Ross The west wing of Boston s Museum of Fine Arts is named after him, his wife, and the Linde family in recognition of the more than 25 million they donated to the museum. ref name Ross He also was a major donor to his alma mater, the Massachusetts Institute of Technology . ref name Ross ref name MIT Linde arrived in Boston in 1958 as an undergraduate at MIT, where he studied civil engineering. ref name Ross He graduated from Harvard Business School in 1964 and went to work for Cabot, Cabot & Forbes . ref name Ross He and Zuckerman redeveloped much of East Cambridge into the area now known as Kendall Square , helping create a U.S. technology hub, with Harvard and MIT researchers mixing with firms such as Google , Microsoft , Biogen Idec , an ... more details
chembox UNII Ref fdacite correct FDA UNII WI638GUS96 verifiedrevid 444634214 ImageFile Dexpramipexole.png ImageSize 200px ImageAlt IUPACName R N sup 6 sup propyl 4,5,6,7 tetrahydrobenzo d thiazole 2,6 diamine OtherNames Section1 Chembox Identifiers CASNo 104632 28 2 CASOther br 104632 27 1 Dihydrochloride PubChem SMILES CCCN C H 1CCC N C N S2 C2C1 Section2 Chembox Properties C 10 H 17 N 3 S 1 Appearance Density MeltingPt BoilingPt Solubility Section3 Chembox Hazards MainHazards FlashPt Autoignition Dexpramipexole KNS 760704 is an experimental drug being investigated by Knopp Biosciences and Biogen Idec for the treatment of amyotrophic lateral sclerosis ALS , also known as Lou Gehrig s disease. In September 2009, it received FDA Fast Track Development Program Fast Track designation for ALS from the U.S. Food and Drug Administration FDA . ref http www.knoppneurosciences.com index.php?section news&subsection news&id 56 FDA Fast Track KNS 760704 for ALS , September 2, 2009 ref It has received Orphan Drug designation by both the FDA and the European Medicines Agency . Dexpramipexole is a low molecular weight, water soluble, orally bioavailable, renally excreted compound with linear pharmacokinetics , and has been shown to be well tolerated in human subject testing. ref Safety, Tolerability, and Pharmacokinetics of KNS 760704 Dexpramipexole in Healthy Adult Subjects. Michael E. Bozik, James L. Mather, William G. Kramer, Valentin K. Gribkoff and Evan W. Ingersoll. J Clin Pharmacol. Published online 19 October 2010. ref KNS 760704 is the chirally pure form of dexpramipexole, which has been shown to improve mitochondrial function and to confer significant cellular protection in neurons under stress. ref KNS 760704 6R 4,5,6,7 tetrahydro N6 propyl 2, 6 benzothiazole diamine dihydrochloride monohydrate for the Treatment of Amyotrophic Lateral Sclerosis. Valentin K. Gribkoff and Michael E. Bozik. CNS Neuroscience & Therapeutics 14 2008 215 226. ref KNS 760704 was originally iden ... more details
Infobox award name MIT150 image caption description The most significant innovators, inventions, or ideas from MIT, MIT alumni, and other MIT related people and organizations ref name MIT150 cite news url http www.boston.com news education higher specials mit150 mitlist ?page full title The MIT 150 150 Ideas, Inventions, and Innovators that Helped Shape Our World publisher The Boston Globe date May 15, 2011 ref presenter Boston Globe host country flagcountry United States of America year 2011 website http www.boston.com news education higher specials mit150 MIT150 The MIT150 is a list published by the Boston Globe , in honor of the 150th anniversary of the Massachusetts Institute of Technology MIT in 2011, listing 150 of the most significant innovators, inventions or ideas from MIT, its alumni, faculty, and related people and organizations in the 150 year history of the institute. The top 30 innovators and inventions on the list are Tim Berners Lee , inventor of the World Wide Web Eric Lander , team leader for sequencing one third of the Human Genome William Shockley , inventor of the solid state electronics solid state transistor Ray Tomlinson , inventor of the symbol use in email addresses Phillip A. Sharp , founder of Biogen Idec Ken Olsen and Harlan Anderson , founders of Digital Equipment Corp. Helen Greiner and Colin Angle , founders of iRobot Corp. Ellen Swallow Richards , nutrition expert, and the first woman admitted to MIT Amar Bose , founder of Bose Corporation Ivan Getting , founder of Aerospace Corp. , inventor of GPS Salvador Luria , father of modern biology Joseph Jacobson , cofounder of E Ink Dan Bricklin , Bob Frankston , inventors of VisiCalc Brewster Kahle , founder of the Internet Archive Daniel Lewin , Tom Leighton , co founders of Akamai Technologies Akamai Vannevar Bush , science advisor to President Franklin D. Roosevelt Pietro Belluschi , dean of the MIT School of Architecture and Planning Ron Rivest , Adi Shamir , Leonard Adleman , inventor ... more details
MALT Orbital Lymphoma Study ref History Developed by the IDEC Pharmaceuticals, which is now part of BiogenIdec , ibritumomab tiuxetan was the first radioimmunotherapy drug approved by the Food and Drug ... rights to sell, market, and distribute this radioimmunotherapy antibody from Biogen for approximately ... more details
br John M. Dunn , executive vice president, new ventures, BiogenIdec br Peter C. Farrell, Ph.D. ... Members include the University of California , Amgen , University of California, Irvine , BiogenIdec , Stanford , Amgen , Genentech and Gilead Sciences . CHI Member List http www.chi.org uploadedFiles ... more details
Drugbox Verifiedfields changed verifiedrevid 458282664 Monoclonal antibody data type mab mab type mab source zu o target CD20 Clinical data tradename pregnancy AU pregnancy US pregnancy category legal AU legal CA legal UK legal US legal status routes of administration Pharmacokinetic data bioavailability protein bound metabolism elimination half life excretion Identifiers CAS number Ref cascite changed ?? CAS number 637334 45 3 ATC prefix none ATC suffix PubChem DrugBank Ref drugbankcite correct drugbank DrugBank UNII Ref fdacite correct FDA UNII A10SJL62JY ChemSpiderID Ref chemspidercite correct chemspider ChemSpiderID NA Chemical data C 6494 H 9978 N 1718 O 2014 S 46 molecular weight 148 kDa Ocrelizumab is a humanize d anti CD20 monoclonal antibody . It targets mature B cell B lymphocyte s ref cite news author K. John Morrow Jr title Methods for Maximizing Antibody Yields url http www.genengnews.com articles chitem.aspx?aid 2514 work Genetic Engineering & Biotechnology News publisher Mary Ann Liebert, Inc. page 36 date 2008 06 15 accessdate 2008 07 06 quote Note information included in this article only found in table present in print version of article. ref and hence is an immunosuppressive drug candidate. It is under development by Hoffmann La Roche s subsidiary Genentech , and Biogen Idec . It had reached Phase III clinical trial s for rheumatoid arthritis ref cite journal pmid 19463076 year 2009 last1 Kausar first1 F last2 Mustafa last3 Sweis last4 Sawaqed last5 Alawneh last6 Salloum last7 Badaracco last8 Niewold last9 Sweiss title Ocrelizumab a step forward in the evolution of B cell therapy volume 9 issue 7 pages 889 95 doi 10.1517 14712590903018837 journal Expert opinion on biological therapy first2 K first3 G first4 R first5 K first6 R first7 M first8 TB first9 NJ ref and lupus erythematosus , ref http www.clinicaltrials.gov ct2 show NCT00539838 A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus BEGIN ref and ... more details
Encyclopedia
top
